MANAGEMENT OF ORAL RECURRENT APHTHOUS STOMATITIS (ORAS)


ABSTRACT
Oral recurrent aphthous stomatitis is the most common oral mucosal disease. Despite much clinical and research attention, the causes remain incompletely understood. Treatment options include no treatment, treatment of associated systemic diseases, topical medications, systemic treatment and palliative treatments. The most effective treatments involve agents that suppress or modulate the immune function. Topical agents are preferred due to its limited side-effects. Adjunct pain control and prevention of secondary infections is sometimes necessary.

Key words: - Oral - recurrent stomatitis – management.

INTRODUCTION
Oral recurrent aphthous stomatitis (ORAS) is a very common oral mucosal disorder of unknown aetiology. To date the causes remain poorly understood; ORAS is not entirely preventable and thus there is no specific management for it.

GENERAL MANAGEMENT
Management efforts are directed towards reducing the symptoms, diminishing the lesion size and duration and in particular prolonging the ulcer-free periods. Before definitive therapy is instituted it is important to manage any existing underlying disorder that might contribute to ORAS such as any underlying systemic disorders and the presence of any triggering factors of ORAS (1).

If stress is felt to be a strong cofactor, consultation with a behavioral therapist or a psychologist/psychiatrist or the use of relaxation techniques will be helpful. A gluten-free diet is advocated for patient’s gluten-enteropathy. Replacement therapy with Iron, Folic acid, vitamins B6 and B12 are used for patients with underlying haematological deficiencies.

PHARMACOLOGICAL THERAPY
Pharmacological therapies that have been used have centered around topical drug and sometimes systemic therapy. Topical therapies include animicrobials, analgesic mouth rinses and gels, topical glucocorticosteroids, immunomodulators and hormones.

The most common topical therapy uses glucocorticoids such as hydrocortisone, triamcinolone, flunisolide, betamethasone and flumethasone (2). These medications reduce symptoms and will not cause hypothalamic-pituitary-adrenal axis suppression when used for less than 3 weeks. Administration of corticosteroids in single daily doses compared with multiple daily doses and on alternate-day regimens will help minimize the suppression (3). The corticosteroids can be applied in the form of solutions, creams, gels, aerosols, perilesional infiltrations or lozenges to be dissolved in the mouth. The results are particularly beneficial especially when application is started in the initial stages of the ulceration.

Triamcinolone (0.05 – 0.1%) and fluocinolone (0.05-0.1%) cream applied 3-5 times a day can reduce ulcer size and number and prolong the ulcer-free period. Vincent & Lilly (4) recommended the use of topical triamcinolone acetate 0.1-0.2% aqueous suspension, 5ml oral rinse and expectorate 4 times daily. Betamethasone 17-benzoate gel improves the symptoms and duration of lesion but for less accessible areas, beclomethasone spray may be useful.

Greater efficacy can be achieved with stronger corticosteroids that are administered for long-lasting, non-healing or major ORAS. For example, clobetasol propionate ointment 0.05% in adhesive paste used 2-3 times daily in patients with persistent major ORAS showed complete remission in 5 of 7 patients; no major side-effects was detected (5).

In more recalcitrant cases systemic prednisolone are used, where a 2-week tapering dose is employed, starting with 60mg (6). The addition of a steroid – sparing drug such as Azathioprine have benefited patients.

Perilesional infiltrations using triamcinolone (0.5mg per 2.5cm² of lesion or 5mg/ml) or hydrocortisone (25mg/ml) may be indicated for large, painful localised lesions which are slow to heal. Dosing may be repeated every 10-15 days for as long as the lesions persist.

Studies using antimicrobial rinses such as tetracycline and chlorhexidine gluconate have reported a reduction in the number of ulcer days and severity of the ulcers, increase in ulcer-free days but have not been able to prevent recurrences(2). In a more recent study(7) Triclosan, an antibacterial agent introduced in toothpastes and mouthrinses, have been shown to reduce significantly the number of ulcers. The severity and frequency of ulcers were also reduced. This has been attributed to the anti-inflammatory effect of the agent.

Analgesic mouthrinses containing benzydamine hydrochloride, an indole-group non-salicylic anti-inflammatory analgesic are also used as a 0.15% rinse 3 times a day although a study has found little value of chlorhexidine mouthwash over placebo in the management of ORAS (8). Also beneficial is dexamethasone elixir (0.5mg/5ml), diphenydramine elixir (12.5mg/5ml) and...
Azelastine hydrochloride helps stabilises cell membranes and has been shown to reduce significantly the frequency of occurrence, the ulcer duration and oral irritation in 43 patients.

Other drugs such as transfer factor, gammaglobulin, recombinant human interferon alpha-2a, monoamine oxidase inhibitors, cromoglycates, isopropinosine, dapsone, zinc sulphate, prostaglandin E-2, acyclovir, lasers (CO2 and Helium-Neon) and LongoVital, a food supplement are amongst the many therapeutic modalities reported to have beneficial effects in the treatment of ORAS. However, besides the high costs in some cases and its side effects, more importantly, the lack of comprehensive clinical testing and standardisation poses a problem.

In summary, the management of ORAS remains non-specific until a principal causal factor can be isolated. Research has been, and will continue to be geared towards this end.

REFERENCES


